The tumor proportion score (TPS), combined positive score (CPS), and soluble forms of programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2) were retrospectively analyzed in patients with RMHNSCC treated with nivolumab.
The positivity rates for TPS (PD-L1), CPS (PD-L1), TPS (PD-L2), and CPS (PD-L2) were 73.8%, 78.2%, 56.4%, and 78.2%, respectively. Patients with high TPS (PD-L1), CPS (PD-L1), or CPS (PD-L1 and PD-L2) showed significantly prolonged progression-free survival. Favorable overall survival was associated with high CPS (PD-L1 and PD-L2) and low soluble PD-L1 and PD-L2 levels. The expressions of tissue and soluble PD-L1/2 were not correlated.
Our study revealed that compared to PD-L1 expression alone, dual expression of PD-L1 and PD-L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.
方法:肿瘤比例评分(TPS),综合阳性评分(CPS),在接受纳武单抗治疗的RMHNSCC患者中,回顾性分析了程序性细胞死亡配体-1(PD-L1)和程序性细胞死亡配体-2(PD-L2)的可溶性形式.
结果:TPS(PD-L1)的阳性率,CPS(PD-L1),TPS(PD-L2),CPS(PD-L2)为73.8%,78.2%,56.4%,78.2%,分别。高TPS(PD-L1)患者,CPS(PD-L1),或CPS(PD-L1和PD-L2)显示无进展生存期显著延长。良好的总生存率与高CPS(PD-L1和PD-L2)和低可溶性PD-L1和PD-L2水平相关。组织和可溶性PD-L1/2的表达无相关性。
结论:我们的研究表明,与单独的PD-L1表达相比,在接受纳武单抗治疗的RMHNSCC患者中,组织或可溶性形式的PD-L1和PD-L2双重表达可能是可行的生物标志物.